New drug ProAgio takes aim at Hard-to-Treat cancers in first human trial
NCT ID NCT05085548
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This early-stage trial tested a new drug called ProAgio in 46 people with advanced solid tumors, including pancreatic cancer, that had already been treated. The main goal was to find a safe dose and check for side effects. The drug targets a protein on blood vessels that feed tumors, aiming to slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Institute
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.